tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Fate Therapeutics Approves Key Proposals at Annual Meeting
PremiumCompany AnnouncementsFate Therapeutics Approves Key Proposals at Annual Meeting
2M ago
Fate Therapeutics Reports Q1 2025 Financial Results
Premium
Company Announcements
Fate Therapeutics Reports Q1 2025 Financial Results
2M ago
Optimistic Buy Rating for Fate Therapeutics Driven by Promising FT819 Therapy and Pipeline Expansion
Premium
Ratings
Optimistic Buy Rating for Fate Therapeutics Driven by Promising FT819 Therapy and Pipeline Expansion
3M ago
FATE Upcoming Earnings Report: What to Expect?
PremiumPre-EarningsFATE Upcoming Earnings Report: What to Expect?
3M ago
Fate Therapeutics receives RMAT designation from FDA for FT819
Premium
The Fly
Fate Therapeutics receives RMAT designation from FDA for FT819
4M ago
Hold Rating for Fate Therapeutics Amid Promising FT819 Developments and Ongoing Uncertainties
Premium
Ratings
Hold Rating for Fate Therapeutics Amid Promising FT819 Developments and Ongoing Uncertainties
5M ago
Hold Rating for Fate Therapeutics Amid Early-Stage Pipeline Uncertainty and Cautious Cash Position
PremiumRatingsHold Rating for Fate Therapeutics Amid Early-Stage Pipeline Uncertainty and Cautious Cash Position
5M ago
Fate Therapeutics price target lowered to $3 from $5 at Stifel
Premium
The Fly
Fate Therapeutics price target lowered to $3 from $5 at Stifel
5M ago
Fate Therapeutics price target lowered to $4 from $5 at Wells Fargo
Premium
The Fly
Fate Therapeutics price target lowered to $4 from $5 at Wells Fargo
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100